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SIONS: Medical treatment costs in the year after initiation on duloxetine decreased 
by a greater amount among duloxetine patients with greater persistence compared to 
those who discontinued early. The ﬁndings underscore the importance of sufﬁcient 
length of therapy for major depressive disorder.
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OBJECTIVES: The overall cost of care for patients with schizophrenia can increase 
considerably, due to management of diseases related to the metabolic syndrome such 
as coronary heart disease (CHD) and diabetes. In the STAR study, aripiprazole is a 
second-generation antipsychotic that has shown relatively less adverse metabolic 
effects than other antipsychotics. The objective of this study is to estimate the avoided 
cost of CHD and diabetes with the use of aripiprazole compared with the standard 
of care (SOC) treatment (olanzapine, quetiapine and risperidone) in Mexico. 
METHODS: Predictions of avoided diabetes and CHD for patients receiving aripip-
razole or SOC were based on risk factor data on metabolic outcomes from the STAR 
study and related published articles. These calculations were applied to the Mexican 
population considering a schizophrenia prevalence of 0.7%. The annual cost per 
patient for the treatment of diabetes and CHD in Mexico was obtained from the 
literature review indexed to 2009 prices using the national consumption index for 
health. Cost calculations were discounted by an annual rate of 3.5% and expressed 
in US dollars at an exchange rate of $13.53 Mexican pesos per dollar. RESULTS: The 
estimated number of avoided cases of diabetes and CHD were of 23.4 and 3.7 per 
1000 treated patients with aripiprazole compared with SOC. If patients were treated 
with aripiprazole as the ﬁrst agent, the accumulated direct avoided costs over a 10 
year period for diabetes would be of US$10 millions and for CHD would be of US$17 
million. This represents total accumulated savings for the Mexican Health Care system 
of US$27 millions during this period. CONCLUSIONS: Usage of aripiprazole in the 
Mexican Health Care system can be translated into a signiﬁcant reduction of health 
care costs due to the favorable metabolic proﬁle of this drug when compared to SOC.
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OBJECTIVES: A new cost-effectiveness model, using head-to-head data, was devel-
oped to validate results from a prior indirect analysis comparing olanzapine with 
ziprasidone in the treatment of schizophrenia from the perspective of a third-party 
payer in the United States. METHODS: A decision analytic modeling approach was 
used to estimate the annual medical costs and health outcomes associated with treat-
ment of schizophrenia with the 2 comparators. The decision-tree structure included 
branches representing key clinical events such as response, relapse, and suicide 
attempts/completion. Patients without response to ﬁrst-line treatment switched to the 
other comparator. Decision-tree probabilities were extracted from a head-to-head 
study and other published clinical literature. Direct medical costs and quality-adjusted 
life years (QALYs) were estimated based on resource use (inpatient, outpatient, 
suicide, and drug costs) and utility weights for initial and relapse episodes, mainte-
nance therapy, and extended episodes of schizophrenia. Disutilities associated with 
adverse events (extrapyramidal symptoms [EPS], we ight gain, and hypotension) were 
also considered. One-way and probabilistic sensitivity analyses were performed. 
RESULTS: First-line treatment with olanzapine was associated with fewer hospital 
days, fewer EPS days, and greater number of QALYs than ﬁrst-line treatment with 
ziprasidone. Drug costs were higher for the olanzapine pathway; however, total costs 
were lower for the olanzapine pathway than the ziprasidone pathway due to cost 
savings associated with better health outcomes and less medical resource use. The 
incremental cost per QALY gained indicated that the olanzapine pathway dominated 
the ziprasidone pathway. The one-way and probabilistic sensitivity analyses conﬁrmed 
the robustness of the model and its results. CONCLUSIONS: The model conﬁrms 
results of the previous model and indicates that olanzapine is associated with better 
expected health outcomes and lower costs than ziprasidone. Despite a potential 
increase in drug costs, treating schizophrenia with olanzapine instead of ziprasidone 
could lead to cost savings for payers in the United States.
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OBJECTIVES: Recent approval by the US Food and Drug Administration of three 
atypical antipsychotics–aripiprazole, quetiapine, and olanzapine–as adjunctive therapy 
in adult patients with MDD makes examination of their cost-effectiveness important 
from a payer perspective. METHODS: We developed a decision-analytic model 
to estimate expected outcomes and economic costs in adults with MDD receiving 
aripiprazole (2–20 mg/day), quetiapine (150 mg/day or 300 mg/day), or olanzapine 
(6–18 mg/day as a ﬁxed-dose combination with ﬂuoxetine [50 mg]) as adjunctive 
therapy to ADT. Cost-effectiveness was assessed in terms of the ratio of the expected 
difference in costs of MDD-related care to the expected difference in clinical response 
(≥50% reduction from baseline in Montgomery-Asberg Depression Rating Scale) at 6 
weeks (i.e., cost per additional responder). Expected costs of MDD-related care 
included study medication, and monitoring and treatment of adverse events. Model 
parameters were estimated using data from Phase III trials and published literature. 
RESULTS: With ADT alone, the expected rate of clinical response at 6 weeks was 
estimated to be 30%. Adjunctive therapy with aripiprazole, quetiapine 150 mg/day, 
quetiapine 300 mg/day, and olanzapine was estimated to increase clinical response at 
6 weeks to 49%, 34%, 38%, and 45%, respectively. Costs of MDD-related care over 
6 weeks were estimated to be $164 for ADT alone, $714 for aripiprazole, $498 for 
quetiapine 150 mg/day, $606 for quetiapine 300 mg/day, and $669 for olanzapine. 
Cost per additional responder (vs ADT) was estimated to be $2798 for aripiprazole, 
$7996 for quetiapine 150 mg/day, $5706 for quetiapine 300 mg/day, and $3324 for 
olanzapine. The cost-effectiveness of adjunctive therapy was most sensitive to the 
estimated rate of clinical response at 6 weeks and the cost of adjunctive therapy. 
CONCLUSIONS: Adjunctive therapy with atypical antipsychotics substantially 
increases clinical response at 6 weeks. Cost per additional responder is lower for 
aripiprazole than quetiapine or olanzapine.
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OBJECTIVES: Schizophrenia is a severe chronic psychiatric disease with high treat-
ment costs and social burden. Iloperidone is a recently FDA approved atypical anti-
psychotic medication for the acute treatment of adult patients with schizophrenia. The 
aim of this study is to compare the efﬁcacy and cost of oral iloperidone with olanzap-
ine and haloperidol in a cohort with acute schizophrenia over a 1 year period. 
METHODS: Published literature and clinical expert opinions were used to populate 
a Markov simulation model using TreeAge Pro 2009 software. The model consists of 
nine 6-week cycles. Clinical response is deﬁned as ≥20% reduction in Positive and 
Negative Syndrome Scale total scores (PANSS-T) from baseline. Responders can exist 
in any of the following health states at the end of any cycle: Response with no adverse 
events (AEs), Response with mild-to-moderate AEs, Response with severe AEs, 
Relapse, Dropout and Suicide. Relapse is deﬁned as an increase in PANSS-T scores 
≥25% following a response period of more than 3 cycles. Efﬁcacy was determined as 
the average time spent in the Response with no AEs or Response with mild-to-mod-
erate AEs states. Direct costs included hospitalization, side effects, drugs and outpa-
tient care costs. RESULTS: The mean time patients spent as responders with no AEs 
or responders with mild-to-moderate AEs was estimated to be 5.76 cycles (241.9 days) 
with iloperidone compared to 5.96 cycles (250.3 days) and 6.17 cycles (259.1 days) 
with haloperidol and olanzapine treatments, respectively. The mean monthly treat-
ment costs were $2521, $2424 and $2292 for iloperidone, haloperidol and olanzapine, 
respectively. CONCLUSIONS: Using a Markov simulation model, olanzapine was 
more effective than either iloperidone or haloperidol with associated lower costs. 
Patients spent on average less time as responders with iloperidone treatment compared 
to haloperidol. These results may be of use when determining the most cost-effective 
treatment strategy for acute schizophrenia.
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OBJECTIVES: To compare the cost-effectiveness of treating early responders versus 
early non-responders to an atypical antipsychotic (risperidone) and the cost-effective-
ness of treating early non-responders maintained on risperidone versus those switched 
to olanzapine. METHODS: This post-hoc analysis used data from a randomized, 
double-blind, 12-week schizophrenia study (HGMN; n = 628). Participants were 
initially assigned to risperidone therapy. Early response was deﬁned as ≥20% improve-
ment on the Positive and Negative Syndrome Scale (PANSS) total score from baseline 
to 2 weeks. Early responders continued on risperidone, whereas early non-responders 
were randomized (double-blind) to continue on risperidone or switch to olanzapine 
for 10 additional weeks. Early responders and early non-responders maintained on 
risperidone were compared on health-state utilities (beneﬁts) and total cost over the 
12-week study; early non-responders maintained on risperidone or switched to olan-
zapine were compared from randomization (10 weeks). Utilities were derived from 
the PANSS and adverse events. Treatment costs were calculated using previous 
methods. A mixed model was used to compare outcomes on utilities. RESULTS: Early 
responders to risperidone had signiﬁcantly greater total utility and lower total treat-
ment costs than early non-responders to risperidone. Compared to early non-respond-
ers who continued on risperidone, those who were switched to olanzapine had 
signiﬁcantly better total utility at endpoint and numerically lower total treatment 
costs, reﬂecting signiﬁcantly lower non-medication treatment cost and higher medica-
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tion cost compared to generic risperidone. CONCLUSIONS: Treatment of early 
responders was more cost-effective than the treatment of early non-responders to 
atypical antipsychotic therapy. The treatment of early non-responders who switched 
to olanzapine was more cost-effective than treatment of early non-responders main-
tained on generic risperidone.
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OBJECTIVES: The purpose was to conduct an economic analysis of escitalopram 
(generic drug) versus sertraline and venlafaxine as standard regimen in treatment of 
major depressive disorder (MDD) in Poland. METHODS: Due to lack of statistically 
signiﬁcant differences in comparisons of escitalopram with sertraline and escitalopram 
with venlafaxine, economic proﬁtability estimation was conducted as a cost-minimi-
sation analysis (CMA). Decision model was created by using TreeAge® Pro. Data 
concerning efﬁcacy and safety of compared therapies was based on the clinical-
effectiveness analysis, which was conducted as systematic literature review. Total 
costs of analysed therapies were estimated from the perspective of both payers in 
Poland (National Health Fund and patient) and also from the social perspective. The 
time horizon of the analysis was 6 months. The costs were not discounted. The stabil-
ity of results was checked in one-way and probabilistic sensitivity analyses. Addition-
ally, optimistic and pessimistic scenarios were prepared. RESULTS: Based on the 
assumptions that clinical effects of compared treatment strategies are the same, the 
results of the cost-minimisation analysis are as following: treatment of one patient 
using escitalopram in the 6 month time horizon is 12.71 PLN more expensive then 
sertraline therapy and 135.95 PLN cheaper then therapy with venlafaxine. One-way 
sensitivity analysis conducted for comparison of escitalopram versus sertraline 
showed that results are sensitive on the prices of medicaments. The sensitivity analysis 
conducted for comparison of escitaloprom versus venlafaxine showed the stability of 
basic results. Therapy with escitalopram is cheaper than with venlafaxine for all 
parameters took into account in the sensitivity analysis. CONCLUSIONS: Escitalo-
pram (generic drug) is costly comparable to sertraline and cheaper option of treatment 
in comparison with venlafaxine in the treatment of major depressive disorder in the 
6 month time horizon.
PMH53
ESTIMATION OF UTILITY GAINED FROM METHADONE MAINTENANCE 
TREATMENT FOR OPIOID DEPENDENCE
Liao DL1, Wang JD1, Huang CY2, Chen PC3
1National Taiwan University, Taipei, Taiwan, 2Bali Psychiatric Center, Taipei, Taiwan, 
3National Taiwan University, Taipei, Taiwan
OBJECTIVES: Opioid addiction is a chronic brain disease with severe withdrawal 
symptoms and decompensated condition in the vicious circle of compulsive drug 
seeking behavior, including needle sharing, psychosocial dysfunction, and criminal 
acts due to ﬁnancial decompensation. Methadone maintenance therapy is the service 
under the concept of harm reduction. We analyzed the estimated utility of prevention 
in the implementation of methadone maintenance therapy introduced in Taiwan since 
2006. METHODS: By using the methadone registry data and the estimation of inci-
dence rates of decompensation with versus without methadone maintenance, the 
expected number of decompensated cases reduced by harm reduction can be calcu-
lated. The utility possibly gained is estimated based on assumption of different values 
of quality of life (QOL) for the decompensation. RESULTS: Based on the imprisoned 
registry of Ministry of Justice and estimations of the Center for Diseases Control, the 
number of heroin addicts in Taiwan was about 100,000, with a total of 15,000 regu-
larly in prison. The yearly number of methadone registry cases reached 15,500 by the 
year-end of 2008. Assuming that annual incidence rates of decompensation were about 
0.1 and 0.7 for heroin addicts with and without methadone therapy, then the annual 
expected number prevented by such treatments would be 9000 with a possible gain 
of utility of 1800 and 4500 QALY (quality-adjusted life year), respectively, depending 
on the reduced utility of 0.2–0.5 for the QOL among decompensated cases. CONCLU-
SIONS: As the annual cost for administration of methadone program was about 
40,000 NTD, which leads to an incremental cost of 66,640 to 166,600 NTD (1 USD 
= 32 NTD) per QALY, without counting the cost of possible harm produced to the 
society by decompensated behaviors. With improved accessibility of methadone main-
tenance therapy, the utility of prevention for the decompensation of heroin addiction 
may be further increased.
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OBJECTIVES: Major depressive disorder (MDD) is a psychiatric condition principally 
characterized by depressive mood, loss of appetite, decreased interest in daily activities, 
sleep, behavioural or attentional disorders, diminution of energy, and feelings of guilt. 
Because MDD is associated with substantial health care costs and productivity losses, 
it wields a considerable economic impact. The aim of this study was to assess, in the 
Canadian context, the economic impact of escitalopram in the treatment of MDD. 
METHODS: A cost-utility analysis was performed over a one-year time horizon from 
societal and health care system perspectives in Canada. A decision tree was developed 
to compare the cost per quality adjusted life year (QALY) associated with the use of 
escitalopram and citalopram. The decision tree, which included patients with MDD 
who had received escitalopram or citalopram as initial treatment, takes into account 
the probability of initial and subsequent treatment remission, of relapse, of suicide 
attempts, and of suicide-related death. Costs included were those of the antidepressant 
drugs, medical visits and hospitalizations, and those associated with remission/non-
remission, relapses, suicide attempts and suicide-related deaths. Costs related to pro-
ductivity loss and societal costs associated with suicide-related deaths were also 
included in the analysis with the societal perspective. Utility values associated with 
remission and non-remission were obtained from the literature. RESULTS: From a 
health care perspective, the incremental cost-utility ratio of escitalopram compared to 
citalopram was estimated at $12,869/QALY. From a societal perspective, escitalopram 
provided more QALYs (+0.0085 QALY/patient) and entailed fewer costs (−$144.70/
patient) compared to citalopram. Deterministic and probabilistic sensitivity analyses 
conﬁrmed the robustness of the base-case results. CONCLUSIONS: The results of 
this economic evaluation indicate that escitalopram is a more cost-effective alternative 
than citalopram to treat MDD from both the health care system and societal 
perspectives.
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OBJECTIVES: The Canadian cost-effectiveness analysis of long-acting risperidone 
versus oral atypical and conventional depot antipsychotics in the treatment of schizo-
phrenia was updated based on results from a study comparing long-acting risperidone 
to depot zuclopenthixol. METHODS: An extensive pharmacoeconomic discrete event 
model was developed to estimate the costs and health beneﬁts of patients treated with 
long-acting risperidone versus oral atypical and conventional depot antipsychotics in 
the treatment of patients with schizophrenia at high-risk of non-compliance over a 
ﬁve-year period. In the original analysis, oral risperidone was considered in the oral 
atypical arm and haloperidol decanoate was considered in the conventional depot arm. 
At the time of the original analysis there were no head-to-head clinical studies which 
compared long-acting risperidone to conventional depots. Since, an open-label, ran-
domized, controlled, assessor-blinded, six-month study comparing long-acting risperi-
done to depot zuclopenthixol has been published. Using these study results, the model 
was updated to consider depot zuclopenthixol as the treatment for the depot compara-
tor arm. The comparator of oral risperidone for the oral atypical arm remained the 
same. RESULTS: The model projected the ﬁve-year cumulative direct costs of 
$155,601, $178,153, and $182,942 (discounted) for long-acting risperidone, oral 
risperidone, and depot zuclopenthixol, respectively. Thus, treatment with long-acting 
risperidone saved approximately $22,552 and $27,341 (discounted) over 5 years 
compared to oral risperidone and depot zuclopenthixol. Moreover, long-acting ris-
peridone resulted in greater decreases in the number of relapses, total time spent in 
psychosis and a greater increase in quality-adjusted-life-years (QALYs) compared to 
oral risperidone or depot zuclopenthixol. Hence, long-acting risperidone is the domi-
nant strategy, being more effective and less costly than oral risperidone or depot 
zuclopenthixol. CONCLUSIONS: Consistent with the original analysis, the current 
analysis demonstrates that long-acting risperidone is a cost-effective option which 
results in better clinical outcomes and lower total health care costs than oral risperi-
done or depot zuclopenthixol.
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OBJECTIVES: This analysis considers the impact of ADHD in adults on 1) labor force 
status, and 2) workplace absenteeism and presenteeism in the US. METHODS: Data 
from the 2009 US National Health and Wellness Survey (NHWS) were used to identify 
all those in the labor force 18 to 49 years of age with a diagnosis of attention deﬁcit 
disorder (ADD) or ADHD. The analysis was in two stages: 1) an evaluation of the 
prevalence of adult ADHD (n = 40,428), and 2) the estimation of logistic regressions 
to assess the contribution of unmedicated/medicated ADHD to labor force status and 
the estimation of ordered probit regressions (n = 25,862) to assess the contribution 
of unmedicated/medicated ADHD to absenteeism and presenteeism. Additional vari-
ables that are considered are socio-demographic status and health risk factors, together 
with the Charlson Comorbidity Index (CCI). RESULTS: An estimated 2.7% had 
diagnosed ADHD. This had a signiﬁcant negative impact on labor force participation 
(odds ratio 0.817), although medicated ADHD had no impact. The presence of 
unmedicated ADHD and medicated ADHD were, however, signiﬁcant at the 1% level 
in both the absenteeism and presenteeism models. Odds ratios in the absenteeism 
model were 4.79 for those with unmedicated ADHD and 3.27 for those with medi-
cated ADHD. These were of a similar magnitude to odds ratios for health risk factors 
(obesity 3.40 and morbid obesity 6.34) but less than the CCI odds ratio 17.43. In the 
presenteeism model, the odds ratios were also signiﬁcant at the 1% level at 8.07 for 
medicated and 6.99 for unmedicated ADHD. CONCLUSIONS: The presence of 
